Sandra Calvin Sells 54,244 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 54,244 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $1,356,100.00. Following the completion of the transaction, the chief accounting officer now owns 54,410 shares of the company’s stock, valued at $1,360,250. The trade was a 49.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Sandra Calvin also recently made the following trade(s):

• On Monday, February 3rd, Sandra Calvin sold 3,348 shares of Travere Therapeutics stock. The shares were sold at an average price of $20.12, for a total transaction of $67,361.76.
• On Wednesday, January 22nd, Sandra Calvin sold 925 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.94, for a total transaction of $17,519.50.
• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.30, for a total transaction of $221,247.00.

Travere Therapeutics Stock Performance

TVTX stock opened at $23.72 on Friday. The company has a 50 day moving average price of $19.14 and a 200 day moving average price of $16.01. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $25.29. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The stock has a market capitalization of $1.85 billion, a PE ratio of -5.21 and a beta of 0.72.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Barclays upped their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Evercore ISI boosted their price target on Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday. Wells Fargo & Company upgraded Travere Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $9.00 to $27.00 in a research note on Monday, October 21st. HC Wainwright lifted their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. Finally, Canaccord Genuity Group upped their target price on shares of Travere Therapeutics from $22.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $27.77.

Institutional Investors Weigh In On Travere Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Sterling Capital Management LLC boosted its holdings in Travere Therapeutics by 859.8% in the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock valued at $41,000 after acquiring an additional 2,115 shares during the last quarter. R Squared Ltd acquired a new position in Travere Therapeutics during the 4th quarter valued at about $53,000. CWM LLC lifted its position in Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after purchasing an additional 3,065 shares during the period. Quarry LP bought a new position in shares of Travere Therapeutics in the 3rd quarter valued at about $105,000. Finally, Ameritas Investment Partners Inc. grew its position in shares of Travere Therapeutics by 9.2% during the 4th quarter. Ameritas Investment Partners Inc. now owns 7,905 shares of the company’s stock worth $138,000 after buying an additional 667 shares during the period.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.